Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 10/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21362122 | 0.86 | MEN1 (0.32) | BRD4CNR2P2RX3KMT2A | |
| SCHEMBL21362259 | 0.84 | BRD4 (0.37) | BRD4CNR2P2RX3 | |
| SCHEMBL21362563 | 0.84 | BRD4 (0.53) | BRD4CNR2P2RX3KMT2AKDM4E | |
| SCHEMBL21362103 | 0.84 | BRD4 (0.46) | BRD4CNR2P2RX3KMT2AKDM4E | |
| SCHEMBL21362169 | 0.83 | BRD4 (0.36) | BRD4CNR2KMT2A | |
| SCHEMBL21362192 | 0.83 | PSEN1 (0.32) | BRD4CNR2 | |
| SCHEMBL21362086 | 0.81 | BRD4 (0.34) | BRD4CNR2KMT2AKCNH2 | |
| SCHEMBL21362559 | 0.80 | BRD4 (0.52) | BRD4CNR2P2RX3KMT2AKDM4E | |
| SCHEMBL21362147 | 0.79 | BRD4 (0.31) | BRD4CNR2 | |
| SCHEMBL21352026 | 0.76 | BRD4 (0.48) | BRD4CNR2P2RX3KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190284192-A1 | NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. (CN) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284192-A1 | NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | MYC, BRD1, BRD3 | BRD4 7/4885CNR2 503/4885P2RX3 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.